Abstract
We present a novel, internally validated nomogram that synergistically combines inflammatory and clinical markers to accurately predict bone metastasis in PCa at initial diagnosis. This practical and cost-effective tool has the potential to aid clinicians in risk stratification, guide personalized diagnostic imaging decisions, and ultimately help reduce unnecessary bone scans, particularly in resource-conscious settings. Our findings underscore the pivotal role of the systemic inflammatory response in PCa metastasis.
Introduction
Prostate cancer (PCa) frequently metastasizes to the bone, a condition that drastically lowers survival rates and quality of life. Currently, clinicians rely on whole-body bone scans ($^{99m}$Tc-MDP SPECT) to detect these metastases. However, these scans are expensive, involve radiation exposure, and have high false-positive rates due to unrelated issues like old fractures or infections. While standard clinical indicators like Total Prostate-Specific Antigen (TPSA) and Gleason scores are used to screen patients, their accuracy remains suboptimal. There is a pressing need for more precise, cost-effective ways to identify which patients actually require advanced imaging, especially in resource-constrained medical settings.
Materials and Methods
The researchers conducted a retrospective study to build and validate a predictive tool called a nomogram. The study utilized a dataset of 803 newly diagnosed PCa patients from The First Affiliated Hospital of Soochow University, China, collected between January 2010 and December 2018. Of these, 214 cases were in the Bone Metastasis Group and 589 were in the Non-Bone Metastasis Group.
The team compared two approaches:
- The Clinical Model: Based only on standard metrics (TPSA and biopsy Gleason grade groups).
- The Comprehensive Model: Integrated clinical metrics with three systemic inflammatory markers: the C-reactive protein-to-albumin ratio (HAR), Fibrinogen (FIB), and Hemoglobin (HB).
Multivariate logistic regression was used to identify independent predictors, and the models were validated using bootstrapping with 1,000 iterations.
Results
The Comprehensive Model outperformed the standard Clinical Model across every metric.
Key results include:
- Discriminative Power: The Comprehensive Model achieved an AUC of 0.874, significantly higher than the Clinical Model’s 0.830 ($P < 0.01$).
- Reclassification Improvement: The researchers reported a Net Reclassification Improvement (NRI) of 8.96% and an Integrated Discrimination Improvement (IDI) of 10.3%, indicating the new model was much better at correctly categorizing borderline patients.
- Clinical Utility: Decision Curve Analysis (DCA) showed that using the Comprehensive Model to decide on bone scans provided a positive net benefit across a wide range of threshold probabilities (5% to 90%).
Discussion
The findings reinforce the "seed and soil" theory of metastasis, where systemic inflammation (reflected in high HAR and FIB) creates a microenvironment that promotes tumor cell motility and "homing" to the bone. Importantly, these inflammatory markers are not meant to replace PSA or Gleason scores but to act as a "force multiplier." Because HAR, FIB, and HB are derived from routine, inexpensive blood tests, this model is highly accessible for smaller or rural clinics.
However, the study has limitations. As a single-center retrospective study, the model requires external validation in diverse global populations. Additionally, the study did not include prostate MRI findings or alkaline phosphatase levels, and it lacks long-term survival data to confirm if using this model improves patient outcomes.
Conclusion
Researchers have developed a Comprehensive Model that significantly improves the prediction of bone metastasis in newly diagnosed prostate cancer patients. By combining standard clinical data with low-cost inflammatory blood markers, this tool potentially spares many patients from unnecessary, expensive, and radiation-heavy bone scans while ensuring high-risk individuals receive necessary diagnostic imaging.
Summary updated